News
        Looking for a job in oncology? Check out the BioSpace list of nine companies hiring life sciences professionals like you.
    
        
    
        
    
        
    FEATURED STORIES
        
        
        
    
        Robert F. Kennedy Jr. repeated a series of anti-vaccine talking points during his appearance in front of the Senate finance committee on Thursday, as Democratic and Republican senators alike hammered the Health Secretary on recent COVID-19 vaccine restrictions and his views on Operation Warp Speed. 
    
        
    
        
    
        
    
        As AAV9 and CRISPR programs navigate safety, delivery and scalability hurdles, small molecules offer a deployable, scalable bridge, complementing genetic approaches and accelerating meaningful impact for patients with Duchenne muscular dystrophy.
    
        
    
        
    
        
    
        It can cure deadly diseases, save long-term healthcare costs and transform lives. But the U.S. insurance system still isn’t ready to pay for it.
    
        
    
        
    
        
    Job Trends
        
        
        
    
        2seventy bio, Inc., announced the completion of an asset purchase agreement by Novo Nordisk. Under the terms of the APA, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for the treatment of autoimmune disease.
    
        
    
        
    
        
    FROM OUR EDITORS
        
        
            Read our takes on the biggest stories happening in the industry.
        
        
    
        Novo Nordisk, under new CEO Maziar Mike Doustdar, has a new attitude. It’s making Pfizer livid.
    
        
    
        
    
        
    THE LATEST
    
    
        Phase III data showed that Inluriyo improves progression-free survival versus standard endocrine therapy.
    
        
    
        
    
        
    
        Companies that have broken ground on or are actively constructing manufacturing facilities in the U.S. are exempted from the tariffs, according to President Donald Trump’s social media post on Thursday. 
    
        
    
        
    
        
    
        Though details remain scant, the pending order is expected to be the latest effort in President Donald Trump’s campaign to bring drug prices down to the same level as economically similar countries.
    
        
    
        
    
        
    
        The regulatory greenlight was backed by two Phase III trials that showed normalized growth hormone levels in patients with the rare pituitary condition. It’s the first approval for Crinetics Pharmaceuticals and something CEO Scott Struthers predicted “will transform people’s lives.”
    
        
    
        
    
        
    
        Looking for a biopharma job in Pennsylvania? Check out the BioSpace list of six companies hiring life sciences professionals like you.
    
        
    
        
    
        
    
        The Trump administration’s recently announced fee for new H-1B visa petitions is “completely unreasonable,” an immigration attorney told BioSpace. Attorneys and talent acquisition experts discuss how the fee could impact biopharma and confusion around the proclamation.
    
        
    
        
    
        
    
        Truist analysts called the results “encouraging” while pointing out certain unknowns in the data. Immuneering plans to kick off a registrational trial for atebimetinib later this year. 
    
        
    
        
    
        
    
        The decision to stop the Phase IIb study was driven by “strategic business reasons,” according to a federal clinical trials database.
    
        
    
        
    
        
    
        Three draft recommendation documents published on Wednesday are intended to guide drug sponsors and accelerate the development of cell and gene therapies.
    
        
    
        
    
        
    
        While Harmony management has not disclosed future plans for ZYN002, Jefferies analysts expect the asset to be shelved.